A Prospective, Observational study to evaluate the impact of Type-2-Diabetes on direct oral anticoagulants (DOACs) activity in patients non-valvular atrial fibrillation
Latest Information Update: 22 May 2018
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Pharmacodynamics; Pharmacokinetics
- 22 May 2018 New trial record